Physician profile
Kenya Williams
NPI 1326080144
$22,637.37
in general payments reported to CMS, 2019-2025
21 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 82% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $357 · 2021: $37.61 · 2022: $2,809 · 2023: $11K · 2024: $6,115 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,500 · Consulting Fee: $4,813 · Food and Beverage: $3,117 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,488 · Travel and Lodging: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,500.00 |
| Consulting Fee | $4,812.50 |
| Food and Beverage | $3,117.07 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,487.50 |
| Travel and Lodging | $110.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,483.14 | 2020-2023 | Tepezza |
| Amgen INC. | $5,844.33 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $2,850.91 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $220.50 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Coopervision INC. | $167.00 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.34 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $122.39 | 2024-2025 | Xeomin |
| Intersect Ent, INC. | $104.00 | 2019 | |
| Ethicon US, LLC | $89.62 | 2023-2024 | Prolene, Stratafix |
| Shire North American Group INC | $88.92 | 2019 | |
| Genentech USA, INC. | $79.64 | 2019 | |
| Mallinckrodt Hospital Products INC. | $76.47 | 2024-2025 | Acthar |
| Abbvie INC. | $70.78 | 2023-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $63.46 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $47.21 | 2024-2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $43.81 | 2024 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $35.15 | 2024 | |
| Alcon Vision LLC | $29.31 | 2020 | |
| Sight Sciences, INC. | $25.90 | 2024 | Tearcare System |
| Allergan, INC. | $19.53 | 2021 | |
| Acelrx Pharmaceuticals, INC. | $18.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenya Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.